the disposition of the methotrexate analogue trimetrexate ( tmtx , nsc 352122 ; 2,4-diammino-5-methyl-6- [ ( 3,4,5-trimethoxyanilino ) methyl ] qui nazoline ) was determined in a phase i study in 16 patients with refractory or relapsing cancer .
C0085176
trimetrexate
C0077209
tmtx